HansBiomed Corporation (KOSDAQ:042520)
South Korea · Delayed Price · Currency is KRW 50,400
-100 (-0.20%)
At close: Feb 27, 2026
HansBiomed Income Statement
Financials in millions KRW. Fiscal year is October - September.
Millions KRW. Fiscal year is Oct - Sep.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Operating Revenue | 100,170 | 89,780 | 81,137 | 78,032 | 74,459 | 59,098 |
Other Revenue | - | -0 | - | -0 | -0 | - |
| 100,170 | 89,780 | 81,137 | 78,032 | 74,459 | 59,098 | |
Revenue Growth (YoY) | 24.20% | 10.65% | 3.98% | 4.80% | 25.99% | -26.22% |
Cost of Revenue | 41,455 | 38,266 | 29,391 | 32,909 | 28,776 | 29,869 |
Gross Profit | 58,715 | 51,514 | 51,747 | 45,123 | 45,683 | 29,229 |
Selling, General & Admin | 73,185 | 69,008 | 41,725 | 40,716 | 35,876 | 35,297 |
Research & Development | 5,728 | 5,368 | 4,628 | 5,597 | 5,658 | 7,148 |
Amortization of Goodwill & Intangibles | 264.46 | 295.13 | 367.85 | 342.7 | 286.69 | 384.82 |
Other Operating Expenses | 836.36 | 810.13 | 839.9 | 804.27 | 733.33 | 1,405 |
Operating Expenses | 84,023 | 79,405 | 51,121 | 49,278 | 44,427 | 49,007 |
Operating Income | -25,308 | -27,891 | 625.6 | -4,155 | 1,256 | -19,778 |
Interest Expense | -1,827 | -1,831 | -1,776 | -5,523 | -6,282 | -3,498 |
Interest & Investment Income | 175.49 | 108.67 | 42.43 | 109.3 | 243.24 | 137.62 |
Earnings From Equity Investments | -1,385 | -1,370 | -3,893 | -1,857 | -2,644 | 14.09 |
Currency Exchange Gain (Loss) | 997.13 | 1,216 | -1,037 | -198.83 | 1,852 | 173.91 |
Other Non Operating Income (Expenses) | 499.45 | 2.65 | -524.93 | -11,524 | 9,075 | -2,141 |
EBT Excluding Unusual Items | -26,848 | -29,765 | -6,562 | -23,149 | 3,500 | -25,092 |
Gain (Loss) on Sale of Assets | 10.09 | 12.42 | -73.02 | -16.98 | 1.6 | 54.82 |
Asset Writedown | - | - | 4.4 | -366.16 | - | - |
Other Unusual Items | - | - | - | - | - | 3,420 |
Pretax Income | -26,838 | -29,752 | -6,631 | -23,532 | 3,501 | -21,617 |
Income Tax Expense | 1,346 | 2,323 | 1,169 | 559.59 | -1,421 | 508.78 |
Earnings From Continuing Operations | -28,184 | -32,075 | -7,800 | -24,092 | 4,923 | -22,126 |
Minority Interest in Earnings | 740.04 | 733.77 | 576.77 | 1,047 | 1,224 | 3,837 |
Net Income | -27,444 | -31,341 | -7,223 | -23,045 | 6,147 | -18,289 |
Net Income to Common | -27,444 | -31,341 | -7,223 | -23,045 | 6,147 | -18,289 |
Shares Outstanding (Basic) | 13 | 13 | 13 | 11 | 10 | 10 |
Shares Outstanding (Diluted) | 13 | 13 | 13 | 11 | 13 | 10 |
Shares Change (YoY) | 0.90% | 0.29% | 20.83% | -18.41% | 31.21% | 1.48% |
EPS (Basic) | -2098.06 | -2413.29 | -557.76 | -2150.23 | 624.45 | -1826.69 |
EPS (Diluted) | -2098.06 | -2413.29 | -558.00 | -2150.23 | 180.37 | -1827.00 |
Free Cash Flow | -25,843 | -1,544 | -835.74 | -5,670 | -8,256 | -19,535 |
Free Cash Flow Per Share | -1975.67 | -118.88 | -64.54 | -529.02 | -628.48 | -1951.22 |
Gross Margin | 58.61% | 57.38% | 63.78% | 57.83% | 61.35% | 49.46% |
Operating Margin | -25.26% | -31.06% | 0.77% | -5.33% | 1.69% | -33.47% |
Profit Margin | -27.40% | -34.91% | -8.90% | -29.53% | 8.26% | -30.95% |
Free Cash Flow Margin | -25.80% | -1.72% | -1.03% | -7.27% | -11.09% | -33.06% |
EBITDA | -20,358 | -22,778 | 6,011 | 1,043 | 6,158 | -14,993 |
EBITDA Margin | -20.32% | -25.37% | 7.41% | 1.34% | 8.27% | -25.37% |
D&A For EBITDA | 4,950 | 5,112 | 5,386 | 5,198 | 4,902 | 4,785 |
EBIT | -25,308 | -27,891 | 625.6 | -4,155 | 1,256 | -19,778 |
EBIT Margin | -25.26% | -31.06% | 0.77% | -5.32% | 1.69% | -33.47% |
Advertising Expenses | - | 4,443 | 5,018 | 4,411 | 4,419 | 2,150 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.